Ligand Pharmaceuticals joins Signet-led financing round in Primrose Bio
LGND•Board update
Signet’s James Gale joined Primrose’s board in conjunction with the transaction.
Primrose Bio closes financing round with Signet and Ligand participation
Primrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from Ligand Pharmaceuticals.
Funding is aimed at expanding Primrose’s biologics and mRNA manufacturing technology portfolio to support customer programs toward clinical trials.
Related News
European drugmakers call for faster trials, more spending to compete with US, China
XLV•
Quoin Pharmaceuticals Announces FDA Fast Track Designation For QRX003 For The Treatment Of Peeling Skin Syndrome
QNRX•
